Galena Biopharma Inc. $GALE said that the combination of trastuzumab and neuvax in HER2 low-expressing patients is well-tolerated. The drug-maker said that cardiac effects of trastuzumab are not impacted by addition of NeuVax. There was, however, one CG patient who experienced a grade 3 cardiac adverse event during trial. After 12 months of follow-up combination of trastuzumab and neuvax, the company expects to present first interim efficacy, immunologic outcomes at end of 2017.